association of changes in clinical characteristics and
play

Association of changes in clinical characteristics and management - PowerPoint PPT Presentation

Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction Disclosures Funding: USIK 1995 was funded by Laboratoire Roussel, France USIC 2000


  1. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction Disclosures • Funding: – USIK 1995 was funded by Laboratoire Roussel, France – USIC 2000 was funded by Laboratoire Aventis-France – FAST-MI 2005 and 2010 are registries of the French Society of Cardiology, funded by unrestricted grants from • 2005: Pfizer and Servier (additional grant from the French National Health insurance system) • 2010: Merck, the Daiichi-Sankyo/Eli-Lilly alliance, AstraZeneca, GSK, Novartis, sanofi-aventis • Dr Danchin has received speaking or consulting fees from: AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, Novo-Nordisk, Pfizer, Roche, Sanofi-aventis, Servier, The MedCo

  2. Background The mortality decline in STEMI is usually attributed to increased use of reperfusion therapy. We sought to determine, using four national French databases run 5 years apart, whether other factors, such as temporal changes in patients' characteristics, influenced changes in outcomes, beyond repefusion therapy .

  3. Change in patient profile • Age decreased progressively from 66 to 63 years

  4. Changes in patient behaviour 2000-2010 Less delay from onset to first call/contact 2000 2005 2010 Median 120 90 74 25 th ; 75 th 41; 360 30; 295 30; 240 percentiles Direct MICU call and transportation 60 48,8 50 41,3 40 30 23,2 20 10 0 2000 2005 2010

  5. Change in management: Reperfusion therapy in STEMI patients PPCI Thrombolysis No reperfusion 70 61 % of STEMI patients 60 51 47 50 38 37 40 35 30 29 30 25 23 20 14 12 10 0 1995 2000 2005 2010

  6. Evolution of 30-day mortality 15 Crude 13,7 Standardized for 10 2010 population 11,3 characteristics 8,7 7,6 6,9 5 6,4 4,4 4,4 0 1995 2000 2005 2010

  7. Evolution of 30-day mortality according to use and type of reperfusion therapy 20 18,9 1995 2000 2005 2010 16 11,3 12 10,8 8,7 8,7 8,2 8 6,4 6,3 4,7 4,5 3,2 4 2,1 0 No reperfusion Lysis PPCI Adj. OR (2010 vs 1995) Adj. OR (2010 vs 1995) Adj. OR (2010 vs 1995) 0.47 0.29 0.29 95% CI, 0.32-0.70 95% CI, 0.11-0.76 95% CI, 0.15-0.58

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend